Previous studies have demonstrated that the FA pathway is activated in response to chemotherapeutic agents currently used to treat GBM such as the alkylating agents Temozolomide (TMZ) and BCNU [18], and others have shown that FA-deficient cells are more sensitive to these agents than FA-proficient cells [18, 19]. This evidence concerns the gene FANCA and glioblastoma.